This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jhaveri, F. M. Articles by Levin, H. S. Search for Related Content PubMed PubMed Citation Articles by Jhaveri, F. M. Articles by Levin, H. S.

Declining Rates of Extracapsular Extension After Radical Prostatectomy: Evidence for Continued Stage Migration

From the Section of Urologic Oncology, Department of Urology, and Departments of Radiation Oncology and Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH.

Address reprint requests to Eric A. Klein, MD, Department of Urology, Desk A100, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195; email kleine{at}ccf.org

PURPOSE: Prostate-specific antigen (PSA)-based screening is responsible for a profound clinical stage migration in newly detected prostate cancers. Extracapsular extension (ECE) is an important predictor of outcome after radical prostatectomy (RP). We examined trends in the rate of ECE for cancers detected by PSA screening in 731 RP specimens between 1987 and 1997, when screening became routine urologic practice in the United States.

METHODS: The rates of ECE were examined in 311 prostates with nonpalpable (stage T1c) disease and 420 with palpable but clinically localized (stage T2) disease. Specimens were step-sectioned and examined by a senior pathologist. Rates of ECE were compared with respect to time, and logistic regression was used to identify predictors of ECE.

RESULTS: The rate of ECE decreased from 81% to 36% during the 10-year observation period. Multivariateanalysis involving clinical tumor stage, preoperative serum PSA level, and Gleason score demonstrated that year of treatment was an independent predictor of ECE, with a two-fold reduction of risk occurring during the study period (P < .001; odds ratio, 1.96; 95% confidence interval, 1.37 to 2.78).

CONCLUSION: PSA screening has resulted in a downward trend in pathologic stage in clinically localized prostate cancer, independent of preoperative PSA level, tumor stage, and Gleason score. This time-dependent downward stage migration suggests the need for continuous updating of predictive nomograms and caution in interpreting differences in contemporarily treated patients compared with historical controls. Further study is needed to determine whether this trend will translate into improved disease-free survival.

This article has been cited by other articles:

				P. H Patel and D. R Kockler Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer Ann. Pharmacother., January 1, 2008; 42(1): 91 - 98. [Abstract] [Full Text] [PDF]

				E. A. Klein, C. M. Tangen, P. J. Goodman, S. M. Lippman, and I. M. Thompson Assessing Benefit and Risk in the Prevention of Prostate Cancer: The Prostate Cancer Prevention Trial Revisited J. Clin. Oncol., October 20, 2005; 23(30): 7460 - 7466. [Abstract] [Full Text] [PDF]

				P. C. Albertsen, J. A. Hanley, G. H. Barrows, D. F. Penson, P. D. H. Kowalczyk, M. M. Sanders, and J. Fine Prostate Cancer and the Will Rogers Phenomenon J Natl Cancer Inst, September 7, 2005; 97(17): 1248 - 1253. [Abstract] [Full Text] [PDF]

				J. Melamed, M. W. Datta, M. J. Becich, J. M. Orenstein, R. Dhir, S. Silver, M. Fidelia-Lambert, A. Kadjacsy-Balla, V. Macias, A. Patel, et al. The Cooperative Prostate Cancer Tissue Resource: A Specimen and Data Resource for Cancer Researchers Clin. Cancer Res., July 15, 2004; 10(14): 4614 - 4621. [Abstract] [Full Text] [PDF]

				S. O. Freytag, H. Stricker, J. Pegg, D. Paielli, D. G. Pradhan, J. Peabody, M. DePeralta-Venturina, X. Xia, S. Brown, M. Lu, et al. Phase I Study of Replication-Competent Adenovirus-Mediated Double-Suicide Gene Therapy in Combination with Conventional-Dose Three-Dimensional Conformal Radiation Therapy for the Treatment of Newly Diagnosed, Intermediate- to High-Risk Prostate Cancer Cancer Res., November 1, 2003; 63(21): 7497 - 7506. [Abstract] [Full Text] [PDF]

				H. Augustin, M. Graefen, J. Palisaar, J. Blonski, A. Erbersdobler, F. Daghofer, H. Huland, and P. G. Hammerer Prognostic Significance of Visible Lesions on Transrectal Ultrasound in Impalpable Prostate Cancers: Implications for Staging J. Clin. Oncol., August 1, 2003; 21(15): 2860 - 2868. [Abstract] [Full Text] [PDF]

				P. A. Kupelian, M. Elshaikh, C. A. Reddy, C. Zippe, and E. A. Klein Comparison of the Efficacy of Local Therapies for Localized Prostate Cancer in the Prostate-Specific Antigen Era: A Large Single-Institution Experience With Radical Prostatectomy and External-Beam Radiotherapy J. Clin. Oncol., August 15, 2002; 20(16): 3376 - 3385. [Abstract] [Full Text] [PDF]

				J. Thomas, M. Gupta, Y. Grasso, C. A. Reddy, W. D. Heston, C. Zippe, R. Dreicer, P. A. Kupelian, J. Brainard, H. S. Levin, et al. Preoperative Combined Nested Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen and Prostate-Specific Membrane Antigen Does Not Correlate With Pathologic Stage or Biochemical Failure in Patients With Localized Prostate Cancer Undergoing Radical Prostatectomy J. Clin. Oncol., August 1, 2002; 20(15): 3213 - 3218. [Abstract] [Full Text] [PDF]

				D. D'Souza and M. J. Zelefsky Seed implant brachytherapy for prostate cancer Can. Med. Assoc. J., October 1, 2001; 165(8): 1003 - 1004. [Full Text]

				D. I. Quinn, S. M. Henshall, A.-M. Haynes, P. C. Brenner, R. Kooner, D. Golovsky, J. Mathews, G. F. O'Neill, J. J. Turner, W. Delprado, et al. Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models J. Clin. Oncol., August 15, 2001; 19(16): 3692 - 3705. [Abstract] [Full Text] [PDF]